Source comparison
Stacking BPC-157 & TB-500 Post-Surgical Research: Peptide Comparison
Primary Mechanism VEGF upregulation, nitric oxide signaling, gastric cytoprotection G-actin sequestration, cytokine suppression, cell migration BPC builds vasculature; TB controls inflammation and guides cells to injury site Complementary pathways—different ta
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF upregulation, nitric oxide signaling, gastric cytoprotection
- G-actin sequestration, cytokine suppression, cell migration
- BPC builds vasculature; TB controls inflammation and guides cells to injury site
- Complementary pathways—different targets, same outcome
- Typical Rodent Dose
- 10–50 mcg/kg daily
- 200 mcg/kg–2 mg/kg twice weekly
- Daily vascular stimulus + sustained anti-inflammatory coverage
- BPC acts locally and rapidly; TB sustains systemically
- Half-Life
- <4 hours (serum); tissue retention unknown
- ~10 days (equine data)
- Frequent BPC dosing + infrequent TB dosing balances exposure
- Dosing schedules align naturally without overlap
- Angiogenesis Impact
- Direct VEGFR2 activation, capillary sprouting
- Indirect via endothelial migration, actin reorganization
- Dual angiogenic pathways—receptor-mediated + cytoskeletal
- Faster revascularization than either peptide alone
- Inflammation Control
- Mast cell stabilization, reduced mediator release
- NF-κB suppression, cytokine downregulation
- BPC limits acute release; TB blocks transcription
- Broad-spectrum anti-inflammatory coverage
- Documented Synergy
- 78% collagen improvement (combined) vs 40% (BPC alone) in tendon models
- 85% higher neovascularization (combined) vs single peptides in ischemic models
- Additive or synergistic depending on endpoint
- Real synergy in vascular and structural outcomes—less clear in pure inflammation models